Gufic Biosciences Ltd. Share Price

Overview

Gufic Biosciences Ltd. share price is currently ₹435.69, up by ₹18.37 (4.4%) from its previous closing price of ₹417.32. The share price has gained 4.71% over the past month and gained 20.59% over the past year. The stock's 52-week low and high are ₹263.39 and ₹464.23, respectively. Gufic Biosciences Ltd. has a market capitalisation of ₹ 4,260.00 Cr. The share price was last updated on 18 Sep 2026, 03:30 PM IST.

Gufic Biosciences Ltd.
Gufic Biosciences Ltd.
GUFICBIO
 0.00
 18.37
4.40%
Healthcare
 0.00(%)1D

Updated: 18 Sep 2026, 03:30:00 pm IST

Market Data

Open Price

 422.53

Prev. Close

 417.32
 419.81

Day Low

 435.69

Day High

 263.39

52 Week Low

 464.23

52 Week High

HealthcarePharmaceuticals & Drugs
CategorySmall Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

59.44

Sector PE

44.64

PB Ratio

6.57

Sector PB

5.95

EPS

7.33

Dividend Yield

0.04

Today's Volume

58.587 K

5 Day Avg. Volume

70.252 K

PEG Ratio

-7.61

Market Cap.

₹ 4,260.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 10% at ₹0.1/Share
28-Aug-202628-Aug-2026
DividendsFinal Dividend of 10% at ₹0.1/Share
22-Sep-202522-Sep-2025
DividendsFinal Dividend of 10% at ₹0.1/Share
17-Sep-202419-Sep-2024

Mutual Fund Ownership

Mutual Fund Holder
Jul 26
Shares held
Aug 26
Shares held
ICICI Prudential Multi Cap Fund - Growth-
14.81 Lac
(100%)
Bank of India Small Cap Fund - Regular Plan - Growth5.71 Lac
5.71 Lac
no change
SBI Healthcare Opportunities Fund - Regular Plan - IDCW5.00 Lac
4.00 Lac
(20%)
Bank of India Manufacturing & Infrastructure Fund - Regular Plan - Growth1.99 Lac
2.54 Lac
(27.18%)
Bank of India Business Cycle Fund - Regular Plan - Growth1.46 Lac
1.46 Lac
no change

About Gufic Biosciences Ltd. 👋

Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates in the pharmaceutical segment. It has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
AALGO BREATHS I SEBI RA

AALGO BREATHS I SEBI RA

3 Sep • 7:42 PM · SEBI-Registered Analyst

Gufic Biosciences Ltd – Bullish Setup Near Support

GUFICBIO
The stock is currently consolidating near an important support zone following a recent correction, indicating that selling pressure may be gradually stabilizing. The price action suggests that the stock is attempting to build a base around the ₹428–₹414 support area. If this zone continues to hold, a recovery attempt toward the higher resistance levels could develop. However, confirmation through price action and momentum will remain important before considering the setup stronger. 🔎 Technical View: • Price is holding near the key support zone. • The stock is consolidating after a recent correction. • Sustained buying interest from the support area may indicate improving sentiment. • A decisive breakout above the resistance zone can trigger stronger upside momentum. • Momentum indicators should show further confirmation before the setup gains strength. 🔑 Key Levels: • Support: ₹428 – ₹414 • Resistance: ₹458 – ₹470 🚀 Upside Targets: • ₹470 • ₹485+, subject to a sustained breakout and positive momentum. 📉 Risk: A sustained breakdown below ₹414 may weaken the technical setup and indicate further downside risk. Traders should monitor volume, price action, and overall market conditions closely. ⚠️ For educational purposes only. Not a buy/sell recommendation. — AALGO BREATHS 📊

See More
Saurabh Tyagi--Clovek,Advisory

Saurabh Tyagi--Clovek,Advisory

24 Aug • 11:23 AM · SEBI-Registered Analyst

GUFICBIO
announced Q1FY27 results Consolidated Financial

GUFICBIO
announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: Recorded at Rs 26,081.80 lakh in Q1FY27, representing a growth of 16.58% YoY compared to Rs 22,372.25 lakh in Q1FY26 and a growth of 3.57% QoQ compared to Rs 25,181.97 lakh in Q4FY26. Other Income: Reported at Rs 45.75 lakh in Q1FY27, as against Rs 92.52 lakh in Q1FY26 and a loss of Rs 117.37 lakh in Q4FY26. Total Income: Stood at Rs 26,127.55 lakh in Q1FY27, an increase of 16.30% YoY from Rs 22,464.77 lakh and up 4.24% QoQ from Rs 25,064.59 lakh. Total Profit Before Tax: Earned Rs 3,003.94 lakh in Q1FY27, marking a significant YoY growth of 73.90% from Rs 1,727.41 lakh and a QoQ growth of 3.76% from Rs 2,895.06 lakh. Net Profit for the Period: Recorded at Rs 2,231.28 lakh in Q1FY27, reflecting a 70.71% YoY increase from Rs 1,307.04 lakh and a 1.90% QoQ increase from Rs 2,189.61 lakh. Total Comprehensive Income: Stood at Rs 2,238.81 lakh for Q1FY27 compared to Rs 1,307.04 lakh in Q1FY26 and Rs 2,239.54 lakh in Q4FY26.

See More

Frequently Asked Questions

What is the share price of Gufic Biosciences Ltd.?

What is the market cap of Gufic Biosciences Ltd.?

Should I buy Gufic Biosciences Ltd. stock now?

What is the 52 week high and low of Gufic Biosciences Ltd.?

Is the Gufic Biosciences Ltd. stock good to buy?

Is Gufic Biosciences Ltd. a good buy for the long term?

Is Gufic Biosciences Ltd. overvalued or undervalued?

What is the PE and PB ratio of Gufic Biosciences Ltd.?

Start Now